Valuation: Candel Therapeutics, Inc.

Market Cap 726M 648M 596M 541M 1.03B 68.07B 1.05B 7.13B 2.84B 36.44B 2.73B 2.67B 115B P/E 2026 *
-6.72x
P/E 2027 * -8.16x
Enterprise Value 726M 648M 596M 541M 1.03B 68.07B 1.05B 7.13B 2.84B 36.44B 2.73B 2.67B 115B EV / Sales 2026 *
-
EV / Sales 2027 * 17.3x
Free-Float
85.21%
Yield 2026 *
-
Yield 2027 * -
Nov. 06 Candel Therapeutics Presents Clinical and Biomarker Data for Aglatimagene Besadenovec and Linoserpaturev Across Clinical-Stage Portfolio CI
Oct. 22 Candel Therapeutics, Inc. Appoints Maria Ostrovsky as General Counsel, Effective November 3, 2026 CI
Oct. 01 Candel Therapeutics, Inc. Announces Publication Of Final Phase 2a Clinical Trial Results Of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC CI
Sep. 30 Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Show Durable Local and Systemic Immune Activation After Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer CI
Sep. 30 Candel Therapeutics, Inc. Presents New Biomarker Data From Phase 3 Clinical Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer At ASTRO 2026 CI
Sep. 21 Candel Therapeutics Shares Rise After BofA Upgrade MT
Sep. 21 BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18 MT
Sep. 14 Candel Therapeutics Insider Sold Shares Worth $3,160,783, According to a Recent SEC Filing MT
Sep. 10 Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 CI
Aug. 14 BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 MT
Aug. 13 Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 13 Candel Therapeutics Q2 Loss Widens MT
Aug. 13 Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss MT

Last Transcript: Candel Therapeutics, Inc.

1 day+8.46%
1 week+16.87%
Current month+13.93%
1 month-4.53%
3 months-10.39%
6 months+13.65%
Current year+67.96%
1 week 7.92
Extreme 7.92
9.84
1 month 7.7
Extreme 7.7
10.18
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.77
Extreme 0.77
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 2020-08-31
Director of Finance/CFO 41 2024-01-11
Chief Tech/Sci/R&D Officer 57 2022-09-11
Director TitleAgeSince
Director/Board Member 80 2017-08-31
Director/Board Member 66 2020-08-31
Chairman 70 2021-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

380 0.0005%
9/30/26 Free

Chairman

2,189 0.0029%
9/30/26 Free

Director

1,325 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
+8.46%+16.87%+88.29%+990.80% 670M
+2.24%+8.40%+58.47%+69.00% 66.7B
+4.66%+8.90%+16.93%+85.41% 56.88B
-0.60%+1.73%+24.32%+94.40% 56.53B
+2.55%+15.52%+30.43%+120.17% 46.49B
+2.58%+7.89%+32.49%+45.30% 44.8B
+4.09%+6.37%+228.06%+899.75% 41.59B
-0.47%+9.38%+27.53%+52.40% 35.35B
+3.80%-1.00%+98.16%+66.79% 33.29B
+1.48%+6.21%-38.80%+395.73% 25.1B
Average +2.88%+7.66%+56.59%+281.97% 41B
Weighted average by Cap. +2.30%+7.29%+53.80%+182.88%

Financials

2026 *2027 *
Net sales - 41.92M 37.41M 34.43M 31.25M 59.22M 3.93B 60.69M 412M 164M 2.1B 157M 154M 6.62B
Net income -102M -90.65M -83.41M -75.7M -143M -9.52B -147M -998M -398M -5.1B -381M -373M -16.05B -92.33M -82.41M -75.83M -68.83M -130M -8.65B -134M -907M -362M -4.63B -347M -339M -14.59B
Net Debt - -
Projected Income Statement - Annual - Candel Therapeutics, Inc.
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
26-11-09 $9.490 +8.46% 1,371,305
26-11-06 $8.750 +8.83% 955,020
26-11-05 $8.040 -11.16% 1,228,485
26-11-04 $9.050 +2.61% 993,819
26-11-03 $8.820 +8.62% 3,304,421
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Candel Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.490USD
Average target price
22.11USD
Spread / Average Target
+132.99%
  1. Stock Market
  2. Stocks
  3. CADL Stock